The current revolution in immuno-oncology is being driven by Antibody Drug Conjugates, Immune Checkpoint Inhibitors, Bispecific Antibodies and Cell Therapies. Clinical trials have shown that cancer patients can tolerate this immune-based treatment more effectively than conventional treatments like chemotherapy and radiotherapy. It’s clearly one of the hottest field of Biopharma which has gained momentum in the past few years.
Following the success of our inaugural event, MarketsandMarkets is proud to announce the 2nd Annual Next Gen Immuno-Oncology Congress to be held on 13th and 14th March 2018 at the Thistle London Heathrow Terminal 5 in London, UK. The congress aims to bring academicians, researchers and scientists from research institutespharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in the development of ADC’s, Bispecific Antibodies and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.